Dengue　fever　(DF)　could　develop　into　dengue　haemorrhagic　fever　(DHF)　with　increased　mortality　rate.　Since　the　clinical　characteristics　and　pathogen　are　same　in　DF　and　DHF.　It＇s　important　to　identify　different　molecular　biomarkers　to　predict　DHF　patients　from　DF.　We　conducted　a　clinical　plasma　proteomics　study　using　quantification　(TMT)-based　quantitative　proteomics　methodology　to　found　the　differential　expressed　protein　in　DF　patients　before　they　developed　into　DHF.　In　total　441　proteins　were　identified　up　or　down　regulated.　There　proteins　are　enriched　in　diverse　biological　processes　such　as　proteasome　pathway,　Alanine,　aspartate,　and　glutamate　metabolism　and　arginine　biosynthesis.　Several　proteins　such　as　PLAT,　LAMB2,　and　F9　were　upregulated　in　only　DF　patients　which　developed　into　DHF　cases,　not　in　DF,　compared　with　healthy-control.　In　another　way,　FGL1,　MFAP4,　GLUL,　and　VCAM1　were　upregulated　in　both　DHF　and　DF　cases　compare　with　healthy-control.　RT-PCR　and　ELISA　were　used　to　validate　these　upregulated　gene　expression　and　protein　level　in　54　individuals.　Results　displayed　the　same　pattern　as　proteomics　analysis.　All　including　PLAT,　LAMB2,　F9,　VCAM1,　FGL1,　MFAP4,　and　GLUL　could　be　considered　as　potential　markers　of　predicting　DHF　since　the　levels　of　these　proteins　vary　between　DF　and　DHF.　These　new　founding　identified　potential　molecular　biomarkers　for　future　development　in　precision　prediction　of　DHF　in　DF　patients.